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INTRODUCTION: Catastrophic 
antiphospholipid syndrome (CAPS) is a rare 
complication occurring in 1% of patients 
with Antiphospholipid Syndrome (APS). [4] 
It presents with widespread intravascular 
thrombosis leading to the failure of multiple 
organs (commonly the kidneys, lungs, brain, 
heart, and others. These thromboses are 
caused by antiphospholipid antibodies which 
are thought to induce a hypercoagulable and 
prothrombotic state by acting on endothelial 
cells, platelets, and fibrinolysis. Furthermore, 
the autoantibodies act to activate the 
complement system and ramp up the immune 
system creating a hyper-inflammatory state 
which explains why most patients with CAPS 
will also meet criteria for SIRS. [1] 
Diagnosis of CAPS remains challenging due 
to its clinical overlap with other thrombotic 
microangiopathies. [2] However, diagnostic 
criteria include but are not limited to the 
involvement of three or more organs, 
development of the signs and symptoms 
contemporaneously within one week, biopsy 
demonstrating microangiopathy, and two 
separate serological findings of 
antiphospholipid antibodies separated by six 
weeks. Generally, a diagnosis of Definite 
CAPS is made if all the criteria are met but if 
only three are met the diagnosis is Probable 
CAPS. [1,2,3] Serology can reveal 
anticardiolipin, Lupus Anticoagulant, anti-
β2-glycoprotein I, and antinuclear antibodies. 
[1] 
Management with anticoagulation, 
corticosteroids, plasmapheresis, IVIg, and 
aspirin resulted in a decline in the mortality 
rate from a half to a third of patients. 
Cyclophosphamide produces greater survival 
benefit in patients with SLE. Refractory cases 
can be treated with rituximab or eculizumab 
[4]. Rituximab is thought to be a possible 
alternative treatment due to its ability to 
reduce the detrimental autoantibodies and 
cytokines speculated to be involved in CAPS. 
[5] Here, we report a case of Probable CAPS, 
in the setting of SLE, treated with rituximab 
in addition to most of the standard treatments 
(plasmapheresis, IVIg, glucocorticoids). 
 
CASE REPORT: Previously healthy 18 year 
old African female college student initially 
presented to an outside hospital with 2 week 
history of low grade fevers, erythematous 
rash with blisters on her hands, feet, and face, 
diarrhea (15 bowel movements a day), 
decreased appetite with weight loss, 
shortness of breath, and worsening fatigue 
and weakness. She was diagnosed with Hand 
Foot Mouth disease and discharged 3 days 
later. Three weeks later, her condition 
worsened and she was admitted to the same 
hospital. Labs at the OSH were significant 
for: hgb 10.5, plt 114, PT 16.75, INR 1.58, 
Na 130, tbili 10, dir bili 8.4, ALP 312, AST 
1263, ALT 187, lactate 1.7, HIV neg, CRP < 
0.29, RF < 10. The patient experienced a 
tonic-clonic seizure 4 days after admission 
and was given Ativan and Keppra. She is up 
to date on her immunizations and had no 
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recent sick contacts. She was born in Nigeria 
and moved to the US two and a half years ago 
for college and has not left the US since then. 
After the seizure at the OSH, the patient was 
taken by family to our ED. She was lethargic 
and unresponsive in her car and was brought 
in by ED staff, patient was tachycardic up to 
131, tachypneic up to 50, and hypotensive 
80/50. She was given 3 liters of IVF with 
transient improvement in BP. Due to patient's 
worsening mental status and desaturation, 
she was intubated and required vasopressors 
for hypotension. Labs were significant for 
hgb 7, plt 78, INR 4.3, Na 134, K 3.4, Cl 112, 
HCO3 8, BUN 31, Cr 1.7, alb 1.4, AST 1102, 
ALT 156, alk phos 267, tbili 6.7, CRP 9.3, 
lactate 5.4, procal 73, UA with 74 WBC, 259 
RBC, 5 granular casts on sediment, and UPC 
of 8338 mg/g. CXR showed diffuse bilateral 
interstitial and alveolar opacities. CT chest 
showed patchy bilateral consolidation, 
pleural effusion and axillary/supraclavicular 
LAD. CT head had minimal prominence of 
the temporal horns and third ventricle. CT 
abdomen showed hepatomegaly, inguinal 
LAD, and small amount of free fluid in the 
abd/pelvis. 
Due to worsening respiratory status, patient 
required intubation and mechanical 
ventilation. Her pulmonary edema, elevated 
cardiac enzymes, and renal function (urine 
output and creatinine) worsened even with 
gentle diuresis so she required dialysis. Her 
hospital course was complicated by MSSA 
bacteremia (on HD 8), MSSE bacteremia (on 
HD 32), C. krusei candidemia (on HD 37), 
and CMV Colitis (on HD 46). TEE was 
negative for any other structural or valvular 
abnormalities. She was treated with 
vancomycin, pip-tazo, cefepime, cefazolin, 
ciprofloxacin, metronidazole, fluconazole, 
voriconazole, micafungin, valganciclovir, 
and acyclovir during admission. 
Autoimmune work-up was positive for 
ANA+ (homogeneous 1:640 titer), dsDNA 
96, Chromatin >8, Smith 1.9, Sm RNP 2.5, 
RNP 6.6, Lupus Anticoagulant, Beta-2-
glycoprotein IgA, decreased C3/C4 levels, 
and elevated ESR/CRP. PBS showed 6-9 
schistocytes/hpf. Additional lab work 
showed consistent elevation of PT/PTT, LD 
(1494), normal fibrinogen, haptoglobin, and 
slight decreased ADAMST13 activity (36%). 
On HD6, MRI Brain that showed interval 
development of several significant 
intraparenchymal hematomas with mild mass 
effect (largest in left frontal lobe is 26cc with 
3 mm midline shift) and intraventricular 
extension suggestive of severe coagulopathy. 
Pt was transfused with platelets and pRBC's 
and started on hypertonic saline boluses. 
Patient was treated for Probable CAPS, in the 
setting of SLE, with daily 
hydroxychloroquine, daily 
methylprednisolone 80 mg, 5 cycles of 
plasmapheresis, and 3 cycles of rituximab 
(beginning on HD 16; 375mg/m2 each dose). 
Anticoagulation was held in the setting of the 
patient’s intracerebral hemorrhage and 
frequent bleeding from tracheostomy site. 
Renal biopsy was not performed since the 
patient had thrombocytopenia and 
leukocytosis. Given her positive anti-dsDNA 
antibody, microscopic hematuria, nephrotic 
range proteinuria on UA, and poor renal 
function, patient was treated with 
mycophenolate mofetil for Lupus Nephritis. 
On HD 19, pt had a seizure-like episode and 
Keppra was started. vEEG showed diffuse 
background changes and no evidence of 
seizure. Contrast CT Head was negative for 
abscesses or masses. The patient gradually 
began showing signs of improvement with 
the ability to follow simple commands and 
improvement of laboratory values. Repeat 
CT head demonstrated improving edema and 
resolved midline shift. On HD 52, patient was 
taken off of hemodialysis with good renal 
function and only required hemodialysis on 
HD 58 due to hyperkalemia. 
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R hand rash 
 
R elbow discoid rash 
 
R lower lip mucosal erosion 
L hand rash 
 
R hand rash 
 
T2 AX MRI Brain 
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Noncon CTH 
 
CT Chest on admission with patchy opacities 
and bilateral pleural effusions noted 
 
DISCUSSION: CAPS is a devastating 
syndrome that disproportionately affects 
women at higher rates than men (72% of 
CAPS occur in women). Most cases are 
precipitated by infection, operations, 
stopping anticoagulants, complications of 
pregnancy, and malignancy. Approximately 
half of patients with CAPS have an 
autoimmune disorder and 40% have SLE 
which is a poor prognostic factor. [6] Since 
there was no tissue biopsy demonstrating 
MAHA, the diagnosis was Probable CAPS. 
The kidneys are the most commonly involved 
organ (greater than two thirds of CAPS cases) 
leading to acute kidney failure, proteinuria, 
hematuria, hypertension. Other frequently 
involved organs are the lungs (64%), CNS 
(62%), heart (51%), and skin (50%). [1] Our 
patient exhibited involvement of all these 
organs and the liver on initial presentation; 
furthermore, all of her signs and symptoms 
appeared within the same timeframe. The 
most common laboratory findings are 
antiphospholipid antibodies (especially 
Anticardiolipin IgG and Lupus 
anticoagulant), ANA, and thrombocytopenia. 
Because CAPS causes microangiopathy, 
schistocytes and hemolytic anemia can also 
be seen. All of these laboratory findings, 
except anticardiolipin IgG, were seen in this 
case. [1,2] CAPS is commonly treated with 
anticoagulation, antiplatelet agents, 
corticosteroids, plasmapheresis, and IVIg. 
Plasmapheresis and IVIg remove the 
antiphospholipid antibodies which are 
thought to be the causative agents of CAPS. 
Anticoagulation and antiplatelet agents 
counteract the hypercoagulable and 
prothrombotic state. Corticosteroids relieve 
the ongoing inflammatory processes caused 
by the activation of the complement 
pathways. Additionally, biologic therapies 
have been recommended for the treatment of 
refractory CAPS. Rituximab, an antibody 
against CD20, is thought to reduce B cells 
leading to decreased antiphospholipid 
antibody and cytokine levels. Eculizumab is 
an antibody that inhibits the terminal 
complement pathway thereby decreasing the 
amount of tissue injury and inflammation. 
Case reports and CAPS registry have shown 
resolution of CAPS refractory to standard 
management after use of eculizumab or 
rituximab. [5] Herein, we report the 
improvement of Probable CAPS upon adding 
rituximab to the therapeutic regimen. 
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CONCLUSIONS: This is a life-threatening 
syndrome and as such a high index of 
suspicion and early diagnosis are required in 
order to reduce patient morbidity and 
mortality. [1-3] Standard treatments with 
proven survival benefit are anticoagulation, 
antiplatelet agents, corticosteroids, 
plasmapheresis, and IVIg. [4] SLE is a worse 
prognostic factor for CAPS but these patients 
can be treated with cyclophosphamide with 
improved survival. [6] Case reports have 
shown a role for additional biologic therapies 
like eculizumab and rituximab. [4,5,7] 
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